Non Hodgkin Lymphoma Clinical Trial

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Summary

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available

Exclusion Criteria

Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
Exclude one-time consultation type of new patients.

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

2000

Study ID:

NCT02848274

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States More Info
Christiane Querfeld
Contact
[email protected]
Stanford University, School of Medicine
Palo Alto California, 94305, United States More Info
Tatiana Neal
Contact
650-709-7838
[email protected]
Youn H Kim
Principal Investigator
University of Iowa
Iowa City Iowa, 52242, United States More Info
Vincent Liu
Contact
[email protected]
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Tatyana Feldman, MD
Contact
[email protected]
University of Pittsburg
Pittsburgh Pennsylvania, 15260, United States More Info
Oleg Akilov, MD
Contact
[email protected]
University of Texas Southwestern
Dallas Texas, 75390, United States More Info
Heather Wickless
Contact
[email protected]
University of Utah Hospital
Salt Lake City Utah, 84132, United States More Info
David Wada, MD
Contact
[email protected]
Hospital Italiano de Buenos Aires
Buenos Aires , , Argentina More Info
Paula Enz, MD
Contact
[email protected]
Peter MacCallum Cancer Center,
Melbourne , , Australia More Info
Miles Prince, MD
Contact
[email protected]
University of Sao Paulo Medical School
Sao Paulo , , Brazil More Info
Jose Sanches, MD
Contact
[email protected]
Peking University First Hospital
Beijing , , China More Info
Yang Wang, MD
Contact
[email protected]
The University of Tokyo
Tokyo , , Japan More Info
Tomomitsu Miyagaki
Contact
[email protected]
University Hospitals Birmingham
Birmingham , , United Kingdom More Info
Julia Scarisbrick
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

2000

Study ID:

NCT02848274

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.